Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | JAK2 | O60674 | 8/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | WNT1 | P04628 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290885 | 0.87 | JAK2 (0.44) | JAK2JAK3WNT1GSK3BDYRK1A | |
| SCHEMBL4281637 | 0.87 | JAK2 (0.44) | JAK2JAK3WNT1GSK3BDYRK1A | |
| SCHEMBL4287078 | 0.86 | JAK2 (0.42) | JAK2JAK3WNT1GSK3BDYRK1A | |
| SCHEMBL4279789 | 0.86 | JAK2 (0.42) | JAK2JAK3WNT1GSK3BDYRK1A | |
| SCHEMBL4277364 | 0.85 | SYK (0.48) | CHRNA7KCNH2JAK2 | |
| SCHEMBL4281464 | 0.85 | SYK (0.48) | CHRNA7KCNH2JAK2 | |
| SCHEMBL4281990 | 0.85 | JAK2 (0.41) | JAK2JAK3WNT1GSK3BDYRK1A | |
| SCHEMBL4287617 | 0.85 | JAK2 (0.41) | JAK2JAK3WNT1GSK3BDYRK1A | |
| SCHEMBL4278617 | 0.83 | CHRNA7 (0.48) | CHRNA7KCNH2TYK2 | |
| SCHEMBL4282062 | 0.83 | CHRNA7 (0.48) | CHRNA7KCNH2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| EP-2265607-B1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | CHRNA7 4430/4885KCNH2 2389/4885JAK2 1/4885 |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | CHRNA7 4409/4885KCNH2 3103/4885JAK2 1/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | CHRNA7 4368/4885KCNH2 3162/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.